Logo Image
In Brief

Notable Labs hopes for success with Boehringer’s failed AML drug

Volasertib was being developed by Boehringer Ingelheim but the company discontinued the product after a Phase III study in AML failed.

Latest news

Magentiq’s AI-aided colonoscopy tool increases adenoma detection by 7%

Detection and removal of adenomas during colonoscopies reduces the risk of developing colorectal cancer.

MAIA Biotechnology concludes subject enrolment in NSCLC therapy trial

The study will analyse THIO’s clinical efficacy as another primary objective.

Burden of dental diseases rises sharply in UK

More than 12 million adults in England have unmet dental health needs.

Elevation Oncology expands Phase I solid tumour trial to Japan

The trial will assess the tolerability, safety, and initial anti-tumour activity of EO-3021 in patients with solid tumours.

Ocugen’s Stargardt disease therapy trial completes first cohort dosing

The two-phase trial will evaluate the safety of unilateral subretinal administration of OCU410ST in Stargardt disease patients.

Celcuity doses first subject in prostate cancer treatment trial

Measuring radiographic progression-free survival at RP2D is the primary goal of the Phase II portion of the trial.

Mediwound optimistic about wound therapy EscharEx after Phase II VLU trial

The most recent data continues to support the pivotal trial of EscharEx, which is due to launch in the second half of 2024.

EMA CHMP recommends refusal of marketing authorisation for Nezglyal

Nezglyal’s manufacturers, Minoryx Therapeutics and Neuraxpharm Pharmaceuticals, will seek a re-examination for conditional approval.